安罗替尼用于二线治疗EGFR T790M阴性晚期非小细胞肺癌的疗效和安全性分析(4)
[7] Lian Z,Du W,Zhang Y,et al. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer[J]. Thorac Cancer,2020 May 20.[8] Schiller JH,Harrington DP,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. The New England Journal of Medicine ......
您现在查看是摘要页,全文长 2477 字符。